New Advances in Stem Cell Therapy for Osteonecrosis of the Femoral Head

Author(s): Wei Zhou, Ming Qu, Yajie Lv, Jinyu Zhu*.

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Osteonecrosis of the femoral head (ONFH) is a common refractory orthopedic disease with multiple etiologies that more frequently occurs in middle-aged and young people. ONFH is the main cause of hip replacement in young patients. Since Professor Hernigou first reported the use of stem cells in the treatment of early stage ONFH, a large number of studies have demonstrated the potential of stem cells in the treatment of adult patients with ONFH. With the rise of interdisciplinary stem cell therapy combined with platelet-rich plasma therapy, gene therapy or other methods have gradually attracted the attention of researchers. This article summarizes the current advances in stem cell therapy for ONFH, as well as the problems and challenges, which may provide reference for further research.

Keywords: Stem cells, cell therapy, osteonecrosis of the femoral head, mesenchymal stem cells, gene therapy, trauma.

[1]
Tripathy SK, Goyal T, Sen RK. Management of femoral head osteonecrosis: Current concepts. Indian J Orthop 2015; 49(1): 28-45.
[2]
Fei-yan YYXJ. Treatment progress of joint-preserving procedures for femoral head necrosis in the early stage. Fudan Uni J Med Sci 2017; (01): 117-21.
[3]
Afizah H, Hui JH. Mesenchymal stem cell therapy for osteoarthritis. J Clin Orthop Trauma 2016; 7(3): 177-82.
[4]
Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: Regulation of niche, self-renewal and differentiation. Arthritis Res Ther 2007; 9(1): 204.
[5]
Hernigou P, Trousselier M, Roubineau F, et al. Stem cell therapy for the treatment of hip osteonecrosis: A 30-year review of progress. Clin Orthop Surg 2016; 8(1): 1.
[6]
Hernigou P, Beaujean F, Lambotte JC. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br 1999; 81(2): 349-55.
[7]
Ya-jun LRZG. Evaluation of bone marrow mesenchymal stem cells for the treatment of osteonecrosis of femoral head[J]. J Clin Rehab Tissue Eng Res 2013; 17(35): 6327-32.
[8]
Ming C, Min D, Yin Z. Isolation and culture of human bone marrow mesenchymal stem cells and induction of its differentiating into osteo- blasts in vitro. Orthop J of China 2012; (01): 72-4.
[9]
Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411): 143-7.
[10]
Andriolo L, Merli G, Tobar C, et al. Regenerative therapies increase survivorship of avascular necrosis of the femoral head: A systematic review and meta-analysis. Int Orthop 2018; 42(7): 1689-704.
[11]
Li X, Xu X, Wu W. Comparison of bone marrow mesenchymal stem cells and core decompression in treatment of osteonecrosis of the femoral head: a meta-analysis. Int J Clin Exp Pathol 2014; 7(8): 5024-30.
[12]
Lau RL, Perruccio AV, Evans HM, et al. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: A systematic review. BMC Musculoskelet Disord 2014; 15: 156.
[13]
Hernigou P, Flouzat-Lachaniette CH, Delambre J, et al. Osteonecrosis repair with bone marrow cell therapies: State of the clinical art. Bone 2015; 70: 102-9.
[14]
Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002; (405): 14-23.
[15]
Daltro GC, Fortuna V, de Souza ES, et al. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: A five-year follow-up study. Stem Cell Res Ther 2015; 6: 110.
[16]
Tabatabaee RM, Saberi S, Parvizi J, et al. Combining concentrated autologous bone marrow stem cells injection with core decompression improves outcome for patients with early-stage osteonecrosis of the femoral head: A comparative study. J Arthroplasty 2015; 30(9)(Suppl.): 11-5.
[17]
Papakostidis C, Tosounidis TH, Jones E, et al. The role of “cell therapy” in osteonecrosis of the femoral head. A systematic review of the literature and meta-analysis of 7 studies. Acta Orthop 2016; 87(1): 72-8.
[18]
Yuan H, Zhang J, Guo C, et al. Clinical outcomes of osteonecrosis of the femoral head after autologous bone marrow stem cell implantation: a meta-analysis of seven case-control studies. Clinics 2016; 70(2): 110-3.
[19]
Martin JR, Houdek MT, Sierra RJ. Use of concentrated bone marrow aspirate and platelet rich plasma during minimally invasive decompression of the femoral head in the treatment of osteonecrosis. Croat Med J 2013; 54(3): 219-24.
[20]
Xiao ZM, Jiang H, Zhan XL, et al. Treatment of osteonecrosis of femoral head with BMSCs-seeded bio-derived bone materials combined with rhBMP-2 in rabbits. Chin J Traumatol 2008; 11(3): 165-70.
[21]
Schussler SD, Uske K, Marwah P, et al. Controlled Release of Vanadium from a Composite Scaffold Stimulates Mesenchymal Stem Cell Osteochondrogenesis. AAPS J 2017; 19(4): 1017-28.
[22]
Fellows CR, Matta C, Zakany R, et al. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. Front Genet 2016; 7: 213.
[23]
Oedayrajsingh-Varma MJ, van Ham SM, Knippenberg M, et al. Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure [J]. Cytotherapy 2006; 8(2): 166-77.
[24]
Futami I, Ishijima M, Kaneko H, et al. Isolation and characterization of multipotential mesenchymal cells from the mouse synovium [J]. PLoS One 2012; 7(9): e45517.
[25]
Sekiya I, Muneta T, Horie M, et al. Arthroscopic transplantation of synovial stem cells improves clinical outcomes in knees with cartilage defects [J]. Clin Orthop Relat Res 2015; 473(7): 2316-26.
[26]
Brogden KA. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria [J]. Nat Rev Microbiol 2005; 3(3): 238-50.
[27]
Tao W, Shihao Z, Jiyuan D. Status quo and argument of mesenchymal stem cell therapy for osteoarthritis[J]. Academic J Pla Postgraduate Med School 2017; (06): 559-61.
[28]
Homma Y, Kaneko K, Hernigou P. Supercharging allografts with mesenchymal stem cells in the operating room during hip revision [J]. Int Orthop 2014; 38(10): 2033-44.
[29]
Hernigou P, Poignard A, Manicom O, et al. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone [J]. J Bone Joint Surg Br 2005; 87(7): 896-902.
[30]
Hernigou P, Flouzat LC, Delambre J, et al. Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence [J]. Int Orthop 2014; 38(9): 1825-35.
[31]
Hernigou P, Homma Y, Flouzat-Lachaniette C, et al. Cancer Risk Is Not Increased in Patients Treated for Orthopaedic Diseases with Autologous Bone Marrow Cell Concentrate [J]. J Bone Joint Surg Am 2013; 95(24): 2215-21.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2019
Page: [226 - 229]
Pages: 4
DOI: 10.2174/1574888X13666181025120252
Price: $58

Article Metrics

PDF: 25
HTML: 2
EPUB: 1